Please login to the form below

Not currently logged in

Novo Nordisk appoints new senior principal clinical scientist

Stephen Gough joins the Danish diabetes giant
Stephen Gough Novo Nordisk

Novo Nordisk has appointed Stephen Gough as senior principal clinical scientist. 

Gough will be responsible for providing clinical guidance on the development of new molecules and drugs from early stage through to phase III and beyond for obesity and diabetes.

He joins from the Oxford Centre for Diabetes Endocrinology and Metabolism, where he worked with research groups focusing on autoimmunity.

He said: “I am excited to join a company with over 90 years of dedication to finding better treatments for diabetes. 

“I look forward to working with the exceptional scientific team at Novo Nordisk to help translate research into meaningful therapies that makes a difference for patients.”

Alan Moses, CMO of Novo Nordisk, added: “With [Gough's] key clinical expertise, his experience as a researcher focused on patient issues, and his compassion for patients with diabetes, Professor Gough will have a vital role in working toward Novo Nordisk's ambition of changing diabetes.”

1st October 2015

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company
Porterhouse Medical Group

Porterhouse Medical provides medical and scientific communication services to the pharmaceutical industry across the globe, with a focus on solutions...

Latest intelligence

figure 1
The valuable brand
Creating value beyond the pill is both possible and increasingly necessary...
The rise of real-world evidence
Demonstrating efficacy and value requires more than clinical trial data...
Digital health
The untapped potential to transform healthcare...